Clinical trial Recruiting at 2 sites Interventional Ages 18 to 80

Using a neural interface to help people with tetraplegia control devices with their thoughts

Official title: Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis

Run by Massachusetts General Hospital · NCT05724173 · Data updated 2026-11-12

This study is testing a new brain interface that helps people with tetraplegia, especially those with ALS, control devices like computers just by thinking about it.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment3 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations2 sites (Stanford, California and 1 other locations)
StatusRecruiting
StartedOctober 18, 2023
Main results expectedJuly 31, 2027
Study endsJuly 31, 2027
Registry record updatedJune 2, 2026
Trial IDNCT05724173 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 to 80 with a diagnosis of ALS and severe speech impairment.

Probably not a fit

Patients with visual impairments that hinder their ability to use a computer monitor may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the safety and feasibility of the BrainGate2 Neural Interface System, which allows individuals with tetraplegia to control a computer cursor and other assistive devices using their thoughts. Participants will be individuals diagnosed with amyotrophic lateral sclerosis (ALS) who experience severe speech impairment. The study will assess the device's ability to restore certain abilities that are typically reliant on hand movement or speech. The research is conducted at prominent medical institutions to ensure rigorous evaluation and oversight.

Why it matters

Potential benefit: If successful, this technology could significantly enhance the quality of life for patients with severe mobility and communication impairments.

How similar studies have gone: Previous studies using similar neural interface technologies have shown promising results, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Between 18 and 80 years of age.
* Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases.
* Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four months.
* Must be within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.

Exclusion Criteria:

* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
* Chronic oral or intravenous steroids or immunosuppressive therapy
* Other serious disease or disorder that could seriously affect ability to participate in the study

(There are additional exclusion criteria)

Where it's running

  • Stanford University School of Medicine
    Stanford, California, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.